Amydis bags $2.5 million NIH grant to develop first eye test for key ALS biomarker

Shilpa Biologicals and mAbTree Biologics secure ODD from USFDA

Marks significant milestone for breakthrough biologic to treat rare blood cancers

NewcelX and Eledon join forces to advance potential Type 1 diabetes cure

The collaboration will leverage this clinical experience to inform NCEL-101 development, streamline regulatory pathways, and potentially accelerate timelines for achieving durable graft survival comparable to donor human islets

Roche reports Phase III persevERA breast cancer trial results

Giredestrant shows promise despite missing primary goal

Pfizer’s experimental atopic dermatitis drug shows strong Phase 2 results

The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75

Mumbai doctors perform India’s first robotic surgery to fix rare uterine defect in 23 year old

Doctors recommended a robotic Strassmann Metroplasty, a reconstructive surgery that joins the two halves of the uterus into a single cavity capable of supporting pregnancy

EU unveils draft guidance to fast-track clinical trials during public health emergencies

The document, published under the Accelerating Clinical Trials in the EU (ACT EU) initiative, sets out how trials should be conducted when health emergencies disrupt normal research operations

Syntis Bio launches first patient dosing for groundbreaking oral obesity therapy

SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum

Moderna wins EU backing for world’s first combined flu-COVID shot

The decision marks a pivotal moment for the Massachusetts-based biotech giant

Roche’s Fenebrutinib moves closer to being first BTK inhibitor for relapsing and progressive MS

Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology